Saidal et Novo Nordisk lancent la production locale – Le Jeune Indépendant

A strategic memorandum of understanding was signed this Monday between the Saidal Group and Novo Nordisk Algeria, marking a new stage in the local production of high added value medicines, in particular the latest generation insulins. This was stated in a press release from Saidal.

The Saidal Group, a historic player and pillar of the national pharmaceutical industry, and Novo Nordisk, a Danish global giant specializing in the treatment of chronic diseases such as diabetes and obesity, formalized a strategic partnership during a ceremony held at the headquarters of Saidal’s general management, we read in the press release. The agreement, initialed in the presence of Nabila Benygzer née Ouaret, general director of the Saidal Group, and Hamza Benharkat, general director of Novo Nordisk Algeria, is part of a common approach aimed at developing the production and distribution of innovative molecules on the Algerian market, the same source notes.

Executives from the two companies also attended this ceremony, testifying to the importance of this industrial and technological rapprochement. According to the terms of the protocol, this collaboration mainly concerns the local production of latest generation insulins and other treatments resulting from Novo Nordisk research. The stated objective is to realize the establishment of “full process” aseptic production in Algeria, a first in the national pharmaceutical field, made possible thanks to a close technological partnership between the two parties, still according to the same source.

The leaders of the two groups highlight a shared vision of sustainable development and health sovereignty. The partnership is based on a transfer of know-how and technology, the cornerstone of a model described as “win-win” by the signatories.

According to the press release, this strategic alliance is called upon to strengthen local production capacities, while supporting the efforts of the Algerian authorities to guarantee the country’s autonomy in matters of essential medicines.

By combining Novo Nordisk’s global expertise in research and development with the industrial experience and solid roots of the Saidal Group, this cooperation promises to improve Algerian patients’ access to innovative, safe treatments that meet international standards, the press release concluded.